Key Highlights

  • Nuwellis, Inc. (NASDAQ:NUWE) traded at USD 4.75, down 12.20%, in pre-market trading on Wednesday, October 28, 2026, after its release of Tuesday, October 27, 2026 on a published multicentre paediatric Aquadex study.
  • The ULTRA-Peds Registry covered 91 patients at seven hospitals, with 87% surviving the treatment course. The company plans to seek a label expansion from patients weighing 20 kg and above to those weighing 5 kg and above.
  • For the second quarter of 2026, the company's release of Thursday, August 13, 2026 reported revenue of USD 2.0 million, up 14%, a gross margin of 76% and a net loss of USD 4.8 million.
  • Cash was about USD 8.8 million at August 31, 2026 and is expected to fund operations into the third quarter of 2027. Pre-market prices are thin and can change before the 9:30 a.m. ET open.

Pre-Market Move and Its Trigger

The Aquadex system, which removes fluid from patients with fluid overload, is sold by Nuwellis, Inc. (NASDAQ:NUWE), a medical device company. Its pre-market price on Wednesday, October 28, 2026 was USD 4.75, down 12.20%. A release issued at 8:00 a.m. ET on Tuesday, October 27, 2026 announced that Pediatric Nephrology had accepted a multicentre study of Aquadex in children; the findings are favourable, so the price moved against the news. Profit-taking or thin trading looks likelier, though that is an inference. According to the release, the evidence supports a proposed labelling expansion after a completed pre-submission meeting with the FDA. No other announcement dated Wednesday, October 28, 2026 was identified.

How the Latest Results Frame the Move

Of the 91 patients in the ULTRA-Peds Registry, 62% weighed under 10 kg and 41 weighed below 5 kg, and about 86.5% of procedures were completed without interruption. The release of Thursday, August 13, 2026 reported second quarter revenue of USD 2.0 million, up 14%, with United States revenue up 17%, and first half revenue of USD 4.4 million, up 20%. Gross margin was 76% versus 56% a year before, and operating expenses were USD 4.7 million. The USD 4.8 million net loss, including USD 1.7 million of non-cash warrant valuation expense, compares with USD 12.6 million a year earlier. Cash was USD 3.9 million at June 30, 2026, following about USD 12.7 million of gross financing in June and July.

Risks and Signals to Track

Upside: a label covering patients from 5 kg would widen the paediatric population it can treat, gross margin has risen sharply and the Vivian continuous renal replacement therapy system, in development for children as small as 2.5 kg, adds to the pipeline. Downside: quarterly revenue is only USD 2.0 million, no formal financial guidance is given and labelling approval is not assured. Risks named include dilution from further financing, as the runway ends in 2027, regulatory timing and liquidity. Items to follow: the Federal Reserve decision due later on Wednesday, October 28, 2026, the Vivian advisory board meetings on Wednesday, November 18, 2026 and Thursday, November 19, 2026, and any FDA submission.

Where Things Stand

In short, Nuwellis, Inc. (NASDAQ:NUWE) dropped 12.20% pre-market on Wednesday, October 28, 2026 despite a favourable study release of Tuesday, October 27, 2026, consistent with profit-taking and thin trading. Headline figure: the proposed label threshold of 5 kg, against 20 kg today. Catalysts ahead include the Federal Reserve decision due later on Wednesday, October 28, 2026, the Vivian advisory board on Wednesday, November 18, 2026 and Thursday, November 19, 2026, and any FDA filing. Pre-market prices are snapshots that can change, and this is not investment advice.